Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25545941 | 0.91 | LMNA (0.48) | FBP1MAPTLMNAS1PR1ALDH1A1 | |
| SCHEMBL25546325 | 0.89 | S1PR1 (0.50) | FBP1MAPTLMNAS1PR1ALDH1A1 | |
| SCHEMBL25545938 | 0.88 | DYRK1A (0.39) | DYRK1AMAPTLMNATRPV1ALDH1A1 | |
| SCHEMBL25545928 | 0.88 | FBP1 (0.42) | FBP1MAPTLMNAS1PR1ALDH1A1 | |
| SCHEMBL25546030 | 0.88 | FBP1 (0.42) | FBP1MAPTLMNAS1PR1TRPV1 | |
| SCHEMBL25183737 | 0.87 | FBP1 (0.45) | FBP1MAPTTRPV1ALDH1A1MAPK1 | |
| SCHEMBL25546375 | 0.86 | FBP1 (0.44) | FBP1MAPTLMNAS1PR1ALDH1A1 | |
| SCHEMBL18282312 | 0.85 | FBP1 (0.48) | FBP1MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL25545925 | 0.85 | ALDH1A1 (0.42) | FBP1MAPTLMNAS1PR1ALDH1A1 | |
| SCHEMBL25546067 | 0.82 | RIPK2 (0.41) | DYRK1AMAPTLMNAALDH1A1RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | FBP1 735/4885DYRK1A 3417/4885MAPT 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.